Is Cosentyx Approved for Children?
Cosentyx (secukinumab) is FDA-approved for children ages 6 and older with moderate to severe plaque psoriasis.[1] Approval came in June 2023 based on a phase 3 trial (CAIN457M2302) showing similar efficacy and safety to adults, with 75% of kids achieving clear or almost clear skin at week 12 versus 9% on placebo.[1][2] It's dosed by weight: 75 mg, 150 mg, or 300 mg subcutaneous injections every 4 weeks after initial loading.[3]
What About Younger Children or Other Conditions?
Not approved for kids under 6, or for conditions like psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis in any pediatric group—these remain adult-only indications.[1][3] For enthesitis-related arthritis in kids 4+, adult data suggest use, but no specific pediatric approval exists.[4] Off-label use in younger children lacks robust safety data and isn't recommended without specialist oversight.
Common Side Effects in Kids
Trials reported upper respiratory infections (15-26%), diarrhea (6-15%), and throat irritation most often, similar to adults.[2] Serious risks include infections (e.g., tuberculosis screening required), inflammatory bowel disease flares, and rare hypersensitivity.[1][3] No new pediatric-specific signals emerged, but monitoring for infections is key due to immune suppression.
How Does It Compare to Other Kids' Psoriasis Treatments?
| Treatment | Age Approval | Key Differences |
|-----------|--------------|-----------------|
| Cosentyx | 6+ | Targets IL-17A; weekly then monthly dosing; good for scalp/genitals. |
| Stelara (ustekinumab) | 6+ | IL-12/23 inhibitor; every 12 weeks; slightly higher infection risk in trials. |
| Skyrizi (risankizumab) | Not approved for kids | Adult-only; emerging data. |
| Methotrexate | Any age | Oral/weekly injection; more side effects like nausea, liver monitoring. |
| Biologics like Humira | 4+ for some uses | TNF inhibitor; broader approvals but higher infection rates. |
Cosentyx showed faster skin clearance than etanercept in head-to-head pediatric trials.[2][5]
Who Should Avoid It and Monitoring Needs?
Contraindicated in active infections, IBD history, or live vaccines. Pre-treatment TB test, hepatitis screening, and vaccinations advised.[3] Pediatric rheumatologists/dermatologists typically manage, with bloodwork every 3-6 months. Long-term data beyond 2 years is limited.[2]
[1]: FDA Label for Cosentyx
[2]: Novartis Press Release on Pediatric Approval
[3]: Cosentyx Prescribing Information
[4]: American College of Rheumatology Guidelines
[5]: NEJM Pediatric Trial Results